/For Life Sciences – Outcomes4Me
Precision oncology requires precision targeting.
At Outcomes4Me, we’re here to help you deliver on the promise of precision oncology.
The State of Patient Empowerment Report is now live!
Read >
/For Life Sciences – Outcomes4Me
At Outcomes4Me, we’re here to help you deliver on the promise of precision oncology.
Gain customer insights, increase compliance, and drive access to innovative drugs and diagnostics.
Access high-quality, regulatory-grade outcomes data.
Find support for early-stage recruitment and late-stage patient-reported outcomes.
All of the innovation in the world means nothing if it’s not reaching patients.
The Outcomes4Me platform can be used for lead generation, providing multiple opportunities to seamlessly integrate real-time clinical trial updates into each patient’s daily interaction with our content.
Sponsored
We look for proven, innovative partnerships that will empower patients with knowledge, understanding, and self-advocacy during their treatment through to survivorship.
Almost half of our patient users who qualified for genetic testing (based on NCCN Guidelines®) did not receive testing prior to their diagnosis. Through our partnership with Invitae, we can provide state-of-the-art, clinical-grade, next-generation sequencing-based (NGS) genetic testing that comprehensively analyzes more than 80 genes, and provide insights for cancer patients as well as family members who may be at risk.
We believe test results can expand patient access to and eligibility for new and innovative treatments, while also helping to prolong a patient’s life.
Most healthcare insurance companies cover 100% of the cost associated with genomic profile testing, but the data shows that even the most advanced breast cancer patients don’t always understand the specifics of their tumor. Without data like this, a patient will see fewer options for personalized treatment as well as fewer participation opportunities in clinical trials. Through our partnership with Foundation Medicine Inc., we studied more than 200 breast cancer patients and demonstrated a discrepancy between their willingness to get genomic testing and the extent to which it is being offered as part of their treatment plan.
Qualified, pre-screened patients
Complete medical record and eligibility packet for each patient
Easy-to-navigate patient management system
A partnership that’s flexible and adaptable to your needs and outcomes objectives